Vimarsana
Biggest News Aggregation in the World

Two Prior Lines News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Two Prior Lines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Two Prior Lines Today - Breaking & Trending Today

FDA Grants BLA for Dato-DXd to Treat Unresectable, Metastatic HR-Positive, HER2-Negative Breast Cancer - Vimarsana News

FDA Grants BLA for Dato-DXd to Treat Unresectable, Metastatic HR-Positive, HER2-Negative Breast Cancer

Published: April 2, 2024

The decision follows phase 3 trial results that demonstrated improved progression-free survival and confirmed the safety of Dato-DXd in patients with breast cancer.

Source: pharmacytimes.com
Related Topics:
Ken TakeshitaSusan GalbraithDaiichi SankyoSebastian KaulitzkiRandomized StudyVersus InvestigatorParticipants With InoperableTwo Prior Lines
Dato-Dxd Shows Survival Improvements in HR+/HER2– Breast Cancer - Vimarsana News

Dato-Dxd Shows Survival Improvements in HR+/HER2– Breast Cancer

Published: September 29, 2023

The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor–positive (HR+), HER2-negative (HER2–) breast cancer were treated with datopotamab deruxtecan.

Source: ajmc.com
Related Topics:
United StatesKen TakeshitaDaiichi SankyoSusan GalbraithOncology ResearchEastern Cooperative Oncology GroupImage CreditNorth AmericaSouth AmericaRandomized StudyVersus InvestigatorParticipants With InoperableTwo Prior LinesPatients With Locally Recurrent InoperableMetastatic Triple Negative Breast CancerWho Are Not CandidatesWithout Durvalumab Versus InvestigatorPatients With StageDatopotamab DeruxtecanDato DxdTropion Breast01